halofuginone; 7-bromo-6-chloro-3-[3-[(3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one; stenorol; tempostatin
Jump to navigation
Jump to search
Introduction
extracted from plants
Indications
- unclear if any clinical indications; some experimental success
- successfully used in some animal models of fibrotic diseases, & in a human scleroderma trial[2]
- protected mice from experimental autoimmune encephalomyelitis mediated by TH17 cells
Mechanism of action
- inhibits differentiation of T-helper cells (TH17 cells), thus normalizing the TH17 to T-regulatory cell ratio
- appears to affect T-helper cells (TH17 cells) selectively
- activates amino acid starvation response
More general terms
- pharmaceutical angiogenesis inhibitor (angiostatic agent)
- pyridine
- phenol
- ketone
- heterocyclic compound, 2 rings
References
- ↑ Sundrud MS et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 2009 Jun 5; 324:1334. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/19498172 <Internet> http://dx.doi.org/10.1126/science.1172638
- ↑ 2.0 2.1 Pines M et al Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant. 2003 Jul;9(7):417-25. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12869955
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=62891
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=62892
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=62893
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=62894
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=62895
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=400771
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=400772
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=456390
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11591339